Fintech PR
Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development
TAIPEI, Jan. 31, 2024 /PRNewswire/ — Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with significant contributions from Taian Venture Capital, Maxpro and the National Development Fund (Business Angel Investment Program, and Implementation Project for Strengthening Investment in SMEs), with a total investment of approximately 12.5 million. The raised capital will be directed towards the ongoing development of Anbogen’s two main drug candidates, ABT-101 and ABT-301. It is worth mentioning that both of these candidate drugs were supported by the National Research Program for Biopharmaceuticals (NRPB) before Anbogen took over. With the continued endeavor from Anbogen, these candidate drugs are steadily advancing in clinical trials for evaluation of their efficacy.
ABT-101, a HER2-targeting tyrosine kinase inhibitor (TKI), has exhibited substantial potency and safety during its pre-clinical and phase 1b clinical trial. During the pre-clinical study, ABT-101 demonstrated superior selectivity against HER2 exon20 insertion mutation. In the Phase 1b trial, Dr. Tsu-An Hsu, CEO of Anbogen, stated, “Signs of safety and clinical benefits have been observed in non-small cell lung cancer patients, including sustained tumor suppression in patients who previously developed resistance to Enhertu treatment.” ABT-101 has completed the DLT evaluation of 3 dosage groups (100 mg, 150 mg, and 200 mg), and is now advancing to the 250 mg cohort in the phase 1b trial to continue evaluation of safety, tolerability, pharmacokinetics and efficacy. Phase 2 is scheduled to commence upon the completion of phase 1 trial in 2024.
Joe Hsueh, Anbogen’s General Manager, stated, “With bioventure investors support, we aim to expedite ABT-101 development and broaden its use across various solid tumor types (including colorectal, biliary tract, breast, urothelial, and other gastrointestinal cancers) through our basket trial. Furthermore, the integration of Next-Generation Sequencing (NGS) will facilitate our efforts in developing precision medicine for cancers with unmet clinical need, making a substantial contribution to the advancement of the field.”
Additionally, Anbogen is actively progressing ABT-301, a novel small molecule drug that potentiates efficacy of immune checkpoint inhibitors (ICIs). Having completed its phase 1 trial, ABT-301 exhibited superior safety and pharmacokinetic profiles compared to other marketed drugs with similar mechanism of action. Repeated animal studies reveal a surprising synergistic effect when ABT-301 is used in combination with immune ICIs (anti-PD1/anti-PD-L1) in animal models including colorectal cancer of microsatellite stable (MSS). ABT-301 can modulate the tumor microenvironment, increase the number of killer T cells in peripheral blood and infiltrating the tumor, enabling ICIs to overcome the limitations of “cold” tumors and produce immunotherapeutic effects. Additionally, remarkable efficacy of such combination was observed in head and neck cancer, triple-negative breast cancer (TNBC) and liver cancer animal models. Based on these results, Anbogen has initiated preparations for the Phase 2 clinical trial of ABT-301, combining it with ICIs for the treatment of cancer patients.
Furthermore, leveraging years of experience in developing small molecule cancer drugs, Anbogen’s R&D team independently developed the ABT-200 series of small molecule inhibitors targeting pan-KRAS gene mutations. The ABT-200 series is an exciting development in the field of cancer treatment, showing promising advancements in its early stages. This series holds tremendous potential for addressing cancers that currently lack approved KRAS-targeted drugs, including pancreatic cancer and colorectal cancer.
The Series A funding not only reflects the value of Anbogen’s innovative pipeline, but also underscores the company’s commitment to advancing cancer treatment to fulfill the unmet medical needs.
About Anbogen:
Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide. Anbogen, whose founding was proposed by Dr. Joe Shih, aligns with national policies and addresses significant medical needs. We prioritize innovative research and development for diverse cancer types. For more information, please visit www.anbogen.com.
For Media Inquiries, Please Contact:
Angus Wu
Business Development, Vice President
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/anbogen-secures-12-5-million-in-series-a-funding-advancing-precision-oncology-drug-development-302047814.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
Letter from Gatemore Capital Management LLP to Elementis PLC
-
Latest News4 days ago
Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023
-
Latest News4 days ago
Hyosung Heavy Industries Ranked on BNEF’s Energy Storage Tier 1 List
-
Latest News7 days ago
Former Tesla executive Tim Newell is set to spin off Aspiration’s consumer financial services division.
-
Latest News4 days ago
Talino, Chemonics invest in startup Higala, the Philippines’ pioneering inclusive instant payment system
-
Latest News7 days ago
United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%
-
Latest News3 days ago
SAR1.1 Billion Riyadh Real Estate Fund Launched by Ezdihar Real Estate Development & Al-Istithmar Capital
-
Latest News7 days ago
Morgan Stanley B.V. – annual report and financial statements for the financial year ended 31 December 2023